Prognostic value of p53 mutations in patients with locally advanced esophageal carcinoma treated with definitive chemoradiotherapy

Journal of Gastroenterology

Volumn 36, Issue 5, 2001, Pages 303-311

  Ito, T ^a   Kaneko, K ^a   Makino, R ^a   Ito, H ^a   Konishi, K ^a   Kurahashi, T ^a   Kitahara, T ^a   Mitamura, K ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

DNA sequence; Esophageal carcinoma; p53 mutation; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; COBALT 60; DNA; DNA FRAGMENT; FLUOROURACIL; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA SEQUENCE; DRUG INFUSION; DYSPHAGIA; ESOPHAGUS BIOPSY; ESOPHAGUS CARCINOMA; FEMALE; FLUORESCENCE; GENE MUTATION; GENETIC DISORDER; HUMAN; HUMAN TISSUE; LYMPHADENOPATHY; MALE; MEDIASTINUM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; FEMALE; GENES, P53; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; REMISSION INDUCTION; STATISTICS; SURVIVAL RATE;

EID: 0034987331     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005350170095     Document Type: Article

References (49)

1. Surgery of cancer of esophagus
2. Radical lymph node dissection for cancer of thoracic esophagus
3. Long-term result of subtotal esophagectomy with three-field lymphadenectomy for carcinoma of thoracic esophagus
4. Mortality and morbidity rates, postoperative course, quality of life and prognosis after extended radical lymphadendectomy
5. Preoperative chemotherapy and radiation therapy for patients with cancer of the esophagus: A potentially curative approach
6. Nonoperative therapy for squamous-cell cancer of the esophagus
7. Combined therapies for squamous-cell carcinoma of the esophagus, Southwest Oncology Group Study (SWOG-8037)
8. Long-term results of infusional 5-FU, mitomycin-C, and radiation as primary management of esophageal carcinoma
9. Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: Final report
10. Chemoradiotherapy of esophageal carcinoma
11. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells
12. Combined modality infusional chemotherapy with radiation
13. A review of interactions between platinum coordination complexes and ionizing radiation: Implications for cancer therapy
14. Chemoradiation as primary management of esophageal cancer
15. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus
16. p53, cellular gatekeeper for growth and division
17. Predicting response to cancer chemotherapy: The role of p53
18. Prognostic significance of the p53 mutation in esophageal cancer
19. p53 alternations in esophageal cancer: Association with clinicopathological features, risk factor, and survival
20. Prevalence and predictive value of p53 mutation in patients with esophageal squamous cell carcinomas: Prospective clinico-pathological study and survival analysis of 70 patients
21. Genetic alterations in patients with esophageal cancer with short- and long term survival rate after curative esphagectomy
22. p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma
23. Mutation in the p53 tumor suppressor gene: Clues to cancer epidemiology and molecular pathogenesis
24. Computed tomography in the staging of esophageal carcinoma
25. Carcinoma of the esophagus: CT vs MR imaging in determining resectability
26. Comparison of CT and MR imaging in staging of neck metastasis
27. Guidelines for the clinical and pathologic studies on carcinoma of the esophagus
28. Detection of the p53 gene with high sensitivity by fluorescence-based PCR-SSCP analysis using low-pH buffer and automated DNA sequencer in large number of DNA samples
29. SSCP analysis of long DNA fragments in low pH gel
30. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease
31. Free DNA in the serum of cancer patients and the effect of therapy
32. Nonparametric estimation from incomplete observations
33. p53 protein accumulation and p53 gene mutation in oesophageal carcinoma: A molecular and immunohistochemical study with clinicopathological correlations
34. Mutations of p53 in Barrett's esophagus and Barrett's cancer: A prospective study of 98 cases
35. Comparison of p53 and DNA content abnormalities in adenocarcinoma of the oesophagus and gastric cardia
36. p53 protein expression and prognosis in squamous cell carcinoma of the esophagus
37. The significance of c-erb B2 and p53 immunoreactivity in patients with adenocarcinoma of the esophagus
38. Prognostic value of p53 protein in oesophageal adenocarcinoma
39. Association of p53 protein expression with responses and survival of patients with locally advanced oesophageal carcinoma treated with chemoradiotherapy
40. p53 correlates with improved survival in patients with oesophageal carcinoma
41. TP53 gene mutation status in pretreatment biopsies of oesophageal adenocarcinoma has no prognostic value
42. Inactivation of p53 in normal human cell increases G2/M arrest and sensitivity to DNA-damaging agents
43. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients
44. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies
45. p53 mutation as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas
46. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function
47. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus
48. Curative nonsurgical combined treatment of squamous cell carcinoma of the oesophagus
49. Combined modality therapy for esophageal carcinoma: Preliminary results from a large Australian multicenter study